Boehringer Ingelheim Press Releases

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog

Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves

Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session

Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day

Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology

Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment⁺ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF

Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement

Pradaxa® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations

FDA and EMA reaffirm important health benefits and safety of Pradaxa® (dabigatran etexilate) for patients with atrial fibrillation